Brought to you by 
Karyopharm raises $10mm through Series A2 round
07 Dec 2011
Executive Summary
Karyopharm Therapeutics Inc. (cancer, dermatology, inflammatory, and viral disease drug development) raised $10mm through its Series A2 round led by original Series A investor Chione Ltd. Proceeds will be used to advance the company's first oral selective inhibitor of nuclear transport (SINE) candidate into Phase I trials for hematologic cancers and solid tumors. Karyopharm was formed in 2008 and raised $20mm in its Series A exactly one year ago.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Karyopharm raises $10mm through Series A2 round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice